{{Rsnum
|rsid=2267715
|Gene=CRHR2
|Chromosome=7
|position=30676471
|Orientation=plus
|GMAF=0.4417
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CRHR2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 50.0 | 43.5 | 6.5
| HCB | 17.8 | 46.7 | 35.6
| JPT | 17.8 | 35.6 | 46.7
| YRI | 0.0 | 11.3 | 88.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 17.8 | 46.7 | 35.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2267715
|Name_s=
|Gene_s=CRHR2
|Feature=Intron
|Evidence=PubMed ID:18408560
|Annotation=This variant in the corticotropin-releasing hormone receptor-2 gene was associated with acute bronchodilator response in the 608-participant Childhood Asthma Management Program (CAMP), but was not found to be associated in the 427-participant Sepracor study or the 152-participant LODO trial. The mean ages of the participants in the CAMP, Sepracor, and Lodo cohorts were 8.9, 32.6, and 42.9 years of age, respectively. Only Caucasians were analyzed in each of these studies.
|Drugs=salbutamol
|Drug Classes=SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA161614216
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2267715
|overall_frequency_n=45
|overall_frequency_d=128
|overall_frequency=0.351562
|n_genomes=27
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24123648
|Title=Corticotropin releasing hormone receptor 2 (CRHR-2) gene is associated with decreased risk and severity of posttraumatic stress disorder in women
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}